Company Anacor Pharmaceuticals Inc
Equities
US0324201013
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
|
2016 | Anacor Pharmaceuticals : received rival bid before Pfizer deal - filing | RE |
2016 | Anacor Pharmaceuticals : Pfizer to buy Anacor in $5.2 billion deal for access to eczema gel | RE |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Douglas Giordano
CEO | Chief Executive Officer | 61 | 16-06-23 |
Chief Tech/Sci/R&D Officer | 77 | 04-01-31 | |
Director/Board Member | - | 16-06-23 | |
General Counsel | 75 | 09-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Douglas Giordano
CEO | Chief Executive Officer | 61 | 16-06-23 |
Bryan Supran
BRD | Director/Board Member | - | 16-06-23 |
Director/Board Member | - | 16-06-23 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 45,366,886 | 42,957,738 ( 94.69 %) | 0 | 94.69 % |
Company contact information
![address Anacor Pharmaceuticals Inc](https://cdn.zonebourse.com/static/address/6880500.png)
Sector
1st Jan change | Capi. | |
---|---|---|
+23.50% | 45.01B | |
+47.19% | 40.96B | |
-5.16% | 38.62B | |
+36.37% | 32.6B | |
-7.79% | 27.49B | |
+18.06% | 27.17B | |
+47.29% | 14.61B | |
+41.91% | 12.95B | |
-1.02% | 11.36B |
- Stock Market
- Equities
- Stock
- Company Anacor Pharmaceuticals Inc